These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 17482818

  • 1. Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.
    Perni RB, Chandorkar G, Cottrell KM, Gates CA, Lin C, Lin K, Luong YP, Maxwell JP, Murcko MA, Pitlik J, Rao G, Schairer WC, Van Drie J, Wei Y.
    Bioorg Med Chem Lett; 2007 Jun 15; 17(12):3406-11. PubMed ID: 17482818
    [Abstract] [Full Text] [Related]

  • 2. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
    Slater MJ, Amphlett EM, Andrews DM, Bamborough P, Carey SJ, Johnson MR, Jones PS, Mills G, Parry NR, Somers DO, Stewart AJ, Skarzynski T.
    Org Lett; 2003 Nov 27; 5(24):4627-30. PubMed ID: 14627400
    [Abstract] [Full Text] [Related]

  • 3. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S, Njoroge FG, Girijavallabhan VM, Madison VS, Yao NH, Prongay AJ, Butkiewicz N, Pichardo J.
    J Med Chem; 2005 Aug 11; 48(16):5088-91. PubMed ID: 16078825
    [Abstract] [Full Text] [Related]

  • 4. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
    Ortqvist P, Peterson SD, Kerblom E, Gossas T, Sabnis YA, Fransson R, Lindeberg G, Helena Danielson U, Karlén A, Sandström A.
    Bioorg Med Chem; 2007 Feb 01; 15(3):1448-74. PubMed ID: 17113777
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
    Ding CZ, Zhang YK, Li X, Liu Y, Zhang S, Zhou Y, Plattner JJ, Baker SJ, Liu L, Duan M, Jarvest RL, Ji J, Kazmierski WM, Tallant MD, Wright LL, Smith GK, Crosby RM, Wang AA, Ni ZJ, Zou W, Wright J.
    Bioorg Med Chem Lett; 2010 Dec 15; 20(24):7317-22. PubMed ID: 21067923
    [Abstract] [Full Text] [Related]

  • 6. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G, Sandström A, Akerblom E, Danielson UH.
    Antivir Ther; 2007 Dec 15; 12(5):733-40. PubMed ID: 17713156
    [Abstract] [Full Text] [Related]

  • 7. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
    Li X, Zhang YK, Liu Y, Zhang S, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Liu L, Bu W, Kazmierski WM, Wright LL, Smith GK, Jarvest RL, Duan M, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni ZJ, Zou W, Wright J.
    Bioorg Med Chem Lett; 2010 Dec 15; 20(24):7493-7. PubMed ID: 21041080
    [Abstract] [Full Text] [Related]

  • 8. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S, Robertson K, Hernando JI, DiMuzio J, Summa V.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2295-8. PubMed ID: 19285390
    [Abstract] [Full Text] [Related]

  • 9. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
    Nair LG, Sannigrahi M, Bogen S, Pinto P, Chen KX, Prongay A, Tong X, Cheng KC, Girijavallabhan V, George Njoroge F.
    Bioorg Med Chem Lett; 2010 Jan 15; 20(2):567-70. PubMed ID: 20004570
    [Abstract] [Full Text] [Related]

  • 10. The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.
    Ontoria JM, Di Marco S, Conte I, Di Francesco ME, Gardelli C, Koch U, Matassa VG, Poma M, Steinkühler C, Volpari C, Harper S.
    J Med Chem; 2004 Dec 16; 47(26):6443-6. PubMed ID: 15588076
    [Abstract] [Full Text] [Related]

  • 11. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
    Binder J, Tetangco S, Weinshank M, Maegley K, Lingardo L, Diehl W, Love R, Patick AK, Smith GJ.
    Antiviral Res; 2011 Aug 16; 91(2):102-11. PubMed ID: 21620899
    [Abstract] [Full Text] [Related]

  • 12. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V.
    J Med Chem; 2006 Feb 09; 49(3):995-1005. PubMed ID: 16451065
    [Abstract] [Full Text] [Related]

  • 13. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
    Llinàs-Brunet M, Bailey MD, Ghiro E, Gorys V, Halmos T, Poirier M, Rancourt J, Goudreau N.
    J Med Chem; 2004 Dec 16; 47(26):6584-94. PubMed ID: 15588093
    [Abstract] [Full Text] [Related]

  • 14. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG, Chen KX, Shih NY, Piwinski JJ.
    Acc Chem Res; 2008 Jan 16; 41(1):50-9. PubMed ID: 18193821
    [Abstract] [Full Text] [Related]

  • 15. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA, Rudd MT, Nguyen KT, McIntyre CJ, Romano JJ, Bush KJ, Varga SL, Ross CW, Carroll SS, DiMuzio J, Stahlhut MW, Olsen DB, Lyle TA, Vacca JP, Liverton NJ.
    Angew Chem Int Ed Engl; 2008 Jan 16; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract] [Full Text] [Related]

  • 16. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.
    Lei YF, Yin W, Yang J, Lv X, Wei SH, An QX, Hu XB, Xu ZK.
    Acta Virol; 2008 Jan 16; 52(3):133-41. PubMed ID: 18999887
    [Abstract] [Full Text] [Related]

  • 17. Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors.
    Chung V, Carroll AR, Gray NM, Parry NR, Thommes PA, Viner KC, D'Souza EA.
    Antimicrob Agents Chemother; 2005 Apr 16; 49(4):1381-90. PubMed ID: 15793116
    [Abstract] [Full Text] [Related]

  • 18. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA, Perni RB.
    Curr Opin Drug Discov Devel; 2006 Sep 16; 9(5):606-17. PubMed ID: 17002221
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
    Boloor A, Hanway D, Joshi M, Winn DT, Mendez G, Walls M, Wei P, Qian F, Zhang X, Zhang Y, Hepperle ME, Li X, Campbell DA, Betancort JM.
    Bioorg Med Chem Lett; 2009 Oct 01; 19(19):5708-11. PubMed ID: 19713109
    [Abstract] [Full Text] [Related]

  • 20. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease.
    Pompei M, Francesco ME, Koch U, Liverton NJ, Summa V.
    Bioorg Med Chem Lett; 2009 May 01; 19(9):2574-8. PubMed ID: 19328685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.